Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole and Everolimus in Advanced or Recurrent Endometrial Cancer
NCT01068249Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2010
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in endometrial cancer (EC), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2010; status: active, not recruiting.
02
Drugs
everolimus
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT01068249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01068249.